Interestingly, an inhaled sGC stimulator (MK-5475) also showed significant lung selectivity in a preclinical rat PH model [57] and is under clinical development in PAH (INSIGNIA-PAH (NCT04732221)): this supports the concept of extraordinary lung selectivity of inhaled sGC agonists. Here, SGCB is linked to pulmonary arterial hypertension.